SCHEMBL289448

SCHEMBL289448

CCS(=O)(=O)c1ccc(-c2ccc(CC(C#N)NC(=O)C3(N)CCOCC3)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CTSC P53634 18/20 0.74
KCNH2 Q12809 2/20 0.73
LTB4R Q15722 1/20 0.73
LTB4R2 Q9NPC1 1/20 0.73
CTSK P43235 5/20 0.61
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CTSH P09668 1/20 0.45
CYP2D6 P10635 1/20 0.45
LGMN Q99538 1/20 0.45
CTSL P07711 1/20 0.42
CTSS P25774 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289447 1.00 CTSC (0.74) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL16485746 0.91 CTSC (0.70) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL16485743 0.90 CTSC (0.72) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL16478126 0.90 CTSC (0.72) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL2892617 0.89 CTSC (0.73) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL2892613 0.89 CTSC (0.73) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL2889494 0.86 CTSC (0.82) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL2889495 0.86 CTSC (0.82) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL2893857 0.86 CTSC (0.77) CTSCKCNH2LTB4RLTB4R2CTSK
SCHEMBL2893861 0.86 CTSC (0.77) CTSCKCNH2LTB4RLTB4R2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193239-B2 Substituted 1-cyanoethylheterocyclylcarboxamide compounds ASTRAZENECA AB (SE) 2012-06-05 US claimed
EP-2427445-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 AstraZeneca AB (SE) 2012-03-14 EP claimed
WO-2010128324-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 ASTRAZENECA AB (SE) 2010-11-11 WO claimed
US-20100286118-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 ASTRAZENECA AB (SE) 2010-11-11 US claimed
US-20120329775-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 FORD RHONAN (GB) 2012-12-27 US disclosed
US-8193239-B2 Substituted 1-cyanoethylheterocyclylcarboxamide compounds ASTRAZENECA AB (SE) 2012-06-05 US disclosed
EP-2427445-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 AstraZeneca AB (SE) 2012-03-14 EP disclosed
WO-2010128324-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 ASTRAZENECA AB (SE) 2010-11-11 WO disclosed
US-20100286118-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 ASTRAZENECA AB (SE) 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286118-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 CTSC 1989/4885KCNH2 332/4885LTB4R 881/4885
US-20120329775-A1 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR2 CTSC 1989/4885KCNH2 332/4885LTB4R 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.